The FDA has approved new versions of Pfizer/BioNTech's Comirnaty and Moderna's Spikevax COVID-19 vaccines that target the Omicron KP.2 strain of SARS-CoV-2 which was dominant in the US in r
Shares in Moderna have been under pressure after the company posted a third-quarter loss of $3.6 billion and a steep fall in COVID-19 vaccine sales, although it still thin
The UK's Joint Committee on Vaccinations and Immunisations (JCVI) has said that Moderna's bivalent COVID-19 vaccine should be used for the autumn booster campaign in adults.
BioNTech has responded to a patent infringement lawsuit filed by fellow German biotech CureVac over its COVID-19 vaccine, saying it will "vigorously" defend itself.
Moderna's new version of its COVID-19 vaccine, which targets two virus variants including Omicron, has outperformed the company's original Spikevax shot in a head-to-head clinical trial.
Moderna has reported preliminary clinical results with a bivalent version of its COVID-19 vaccine that combines its original version with another targeting the Beta variant, and seems to of